FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936407465> ?p ?o ?g. }

• W2936407465 endingPage "108864" @default.
• W2936407465 startingPage "108864" @default.
• W2936407465 abstract "Hepatocellular carcinoma (HCC) prognosis remains dismal due to postsurgical recurrence and distant metastasis. Therefore, novel prognostic biomarkers and therapeutic targets for HCC therapy are urgently needed to improve the survival of liver cancer patients. Our evidence suggests that SLC46A3 (the gene solute carrier family 46 (sodium phosphate), member 3) is a member of the SLC46 family and has a potential role in the progression and treatment of HCC. The objective of the present study was to estimate the expression pattern and biological function of SLC46A3 in the progression of HCC, which may serve as a promising biomarker for diagnosis and therapy. In order to determine the expression pattern of SLC46A3 in HCC, several public HCC databases and tissue chips were used to examine 129 sets of primary HCC and non-tumor adjacent tissues from patients who had undergone surgery. The expression of SLC46A3 in 80 sets of HCC and non-tumor adjacent tissues were then compared by RT-PCR and Western Blot. The proliferation, invasion, migration and sphere-forming abilities of SLC46A3 knock-down and overexpressing cell lines were evaluated and the expression of related molecules in the epithelial mesenchymal transition (EMT) were detected by RT-PCR, western blot and immunofluorescence assay. The IC50 value was used to evaluate the effect of SLC46A3 on sorafenib resistance. A lung metastasis model of mice HCC was constructed to test the potential effect of SLC46A3 on cancer metastasis and a subcutaneous xenografted tumor mice model was designed to verify the effect of SLC46A3 on the resistance of HCC cell lines to sorafenib. The expression of SLC46A3 was down-regulated in 83.2% of human HCC tissues compared to non-tumor adjacent tissues. Tumors that expressed low levels of SLC46A3 had more aggressive phenotypes, and patients with these tumors had shorter survival times after surgery compared to patients whose tumors expressed high levels of SLC46A3. Hepatocellular carcinoma cell lines that stably overexpressed SLC46A3 inhibited the levels of migration and invasion compared with control HCC cells, and formed smaller xenograft tumors with more metastases in mice compared with HCC cells that did not overexpress SLC46A3. In addition, overexpression of SLC46A3 obviously inhibited epithelial-to-mesenchymal transition-activating transcription factors such as N-cadherin and Vimentin. Furthermore, descended of IC50 showed that overexpressed SLC46A3 could reduce sorafenib resistance and improve drug response in vivo and in vitro. In conclusion, increased expression of SLC46A3 could favor a better clinical prognosis for patients with HCC, ameliorate sorafenib resistance, and improve drug response. SLC46A3 might serve as a potential prognostic biomarker and therapeutic target in HCC." @default.
• W2936407465 created "2019-04-25" @default.
• W2936407465 creator A5005971604 @default.
• W2936407465 creator A5006762241 @default.
• W2936407465 creator A5011428140 @default.
• W2936407465 creator A5034845046 @default.
• W2936407465 creator A5035886812 @default.
• W2936407465 creator A5047932271 @default.
• W2936407465 creator A5053045844 @default.
• W2936407465 creator A5070859641 @default.
• W2936407465 creator A5074976551 @default.
• W2936407465 creator A5076385283 @default.
• W2936407465 creator A5079533477 @default.
• W2936407465 creator A5080252623 @default.
• W2936407465 date "2019-06-01" @default.
• W2936407465 modified "2023-10-10" @default.
• W2936407465 title "Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy" @default.
• W2936407465 cites W1964211639 @default.
• W2936407465 cites W1979988883 @default.
• W2936407465 cites W1986769086 @default.
• W2936407465 cites W1987473368 @default.
• W2936407465 cites W1988891399 @default.
• W2936407465 cites W1992885568 @default.
• W2936407465 cites W1995164074 @default.
• W2936407465 cites W2003562401 @default.
• W2936407465 cites W2042784094 @default.
• W2936407465 cites W2061568155 @default.
• W2936407465 cites W2063011414 @default.
• W2936407465 cites W2068110847 @default.
• W2936407465 cites W2080773768 @default.
• W2936407465 cites W2081871084 @default.
• W2936407465 cites W2087689543 @default.
• W2936407465 cites W2095866442 @default.
• W2936407465 cites W2112257323 @default.
• W2936407465 cites W2161428444 @default.
• W2936407465 cites W2188563595 @default.
• W2936407465 cites W2267691310 @default.
• W2936407465 cites W2324407602 @default.
• W2936407465 cites W2340909115 @default.
• W2936407465 cites W2466491482 @default.
• W2936407465 cites W2500787525 @default.
• W2936407465 cites W2508113843 @default.
• W2936407465 cites W2557293468 @default.
• W2936407465 cites W2800736774 @default.
• W2936407465 cites W2804700695 @default.
• W2936407465 cites W2891777621 @default.
• W2936407465 doi "https://doi.org/10.1016/j.biopha.2019.108864" @default.
• W2936407465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30981107" @default.
• W2936407465 hasPublicationYear "2019" @default.
• W2936407465 type Work @default.
• W2936407465 sameAs 2936407465 @default.
• W2936407465 citedByCount "18" @default.
• W2936407465 countsByYear W29364074652019 @default.
• W2936407465 countsByYear W29364074652020 @default.
• W2936407465 countsByYear W29364074652021 @default.
• W2936407465 countsByYear W29364074652022 @default.
• W2936407465 countsByYear W29364074652023 @default.
• W2936407465 crossrefType "journal-article" @default.
• W2936407465 hasAuthorship W2936407465A5005971604 @default.
• W2936407465 hasAuthorship W2936407465A5006762241 @default.
• W2936407465 hasAuthorship W2936407465A5011428140 @default.
• W2936407465 hasAuthorship W2936407465A5034845046 @default.
• W2936407465 hasAuthorship W2936407465A5035886812 @default.
• W2936407465 hasAuthorship W2936407465A5047932271 @default.
• W2936407465 hasAuthorship W2936407465A5053045844 @default.
• W2936407465 hasAuthorship W2936407465A5070859641 @default.
• W2936407465 hasAuthorship W2936407465A5074976551 @default.
• W2936407465 hasAuthorship W2936407465A5076385283 @default.
• W2936407465 hasAuthorship W2936407465A5079533477 @default.
• W2936407465 hasAuthorship W2936407465A5080252623 @default.
• W2936407465 hasBestOaLocation W29364074651 @default.
• W2936407465 hasConcept C104317684 @default.
• W2936407465 hasConcept C121608353 @default.
• W2936407465 hasConcept C126322002 @default.
• W2936407465 hasConcept C142724271 @default.
• W2936407465 hasConcept C143998085 @default.
• W2936407465 hasConcept C159654299 @default.
• W2936407465 hasConcept C203014093 @default.
• W2936407465 hasConcept C2776231280 @default.
• W2936407465 hasConcept C2776415932 @default.
• W2936407465 hasConcept C2777546739 @default.
• W2936407465 hasConcept C2778019345 @default.
• W2936407465 hasConcept C2778236600 @default.
• W2936407465 hasConcept C2778695046 @default.
• W2936407465 hasConcept C2779013556 @default.
• W2936407465 hasConcept C2779256057 @default.
• W2936407465 hasConcept C2781197716 @default.
• W2936407465 hasConcept C502942594 @default.
• W2936407465 hasConcept C55493867 @default.
• W2936407465 hasConcept C71924100 @default.
• W2936407465 hasConcept C76419328 @default.
• W2936407465 hasConcept C86803240 @default.
• W2936407465 hasConceptScore W2936407465C104317684 @default.
• W2936407465 hasConceptScore W2936407465C121608353 @default.
• W2936407465 hasConceptScore W2936407465C126322002 @default.
• W2936407465 hasConceptScore W2936407465C142724271 @default.
• W2936407465 hasConceptScore W2936407465C143998085 @default.
• W2936407465 hasConceptScore W2936407465C159654299 @default.

• next